NEUCHÂTEL, Switzerland–(BUSINESS WIRE)– #CataractSurgery–Unlike traditional EDOF lenses, Lucidis® delivers full-range visual performance comparable to a premium trifocal IOL without disturbances.
Category: Business
RevolutionEHR Launches RevPay, Redefining How Optometry Practices Manage Cash Flow
SAN DIEGO–(BUSINESS WIRE)– #DigitalPayments–RevolutionEHR, the market-leading optometry-first operating platform, today announced the launch of RevPay, its fully embedded payments solution designed to help practices get paid effortlessly while recov…
STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million Implantable Col…
Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales
GENEVA–(BUSINESS WIRE)–Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales
Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales
GENEVA–(BUSINESS WIRE)–Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales
Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced today that Ophthalmology and Therapy published a new global narrative re…
NexEos Bio Announces FDA Clearance of IND Application to Proceed to Phase II/III Trial of NTX-1024 in Vernal Keratoconjunctivitis
MALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, today announced that the U.S. Food and Drug Administration…
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity
Alcon Launches TOTAL30 Multifocal for Astigmatism, the World’s Only Monthly Multifocal Toric Contact Lens with Water Gradient Technology
GENEVA–(BUSINESS WIRE)–Alcon Launches TOTAL30 Multifocal for Astigmatism, the World’s Only Monthly Multifocal Toric Contact Lens with Water Gradient Technology
Optometry Practices Elevate Patient Experience with RevolutionEHR’s Integrated, Modernized Patient Portal
SAN DIEGO–(BUSINESS WIRE)– #ONCCompliant–RevolutionEHR launches a modern, compliance-first patient portal that streamlines scheduling, billing, messaging, and records for optometry practices.
Warby Parker to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the fourth quarter and year ended December 31, 2025 will be releas…
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that the first patient has been dosed in t…
Warby Parker Appoints Adrian Mitchell as Chief Financial Officer
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY), a direct-to-consumer lifestyle brand focused on vision for all, today announced the appointment of Adrian Mitchell as Chief Financial Officer, effective February 10, 2026. His appointment stren…
iVeena Delivery Systems Announces Strategic Leadership Promotions to Accelerate Growth and Scientific Innovation
SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems, Inc. (“iVeena”), a clinical-stage ophthalmology company advancing innovative pharmacologic therapies for refractive eye diseases, today announced key executive promotions designed to strengthen …
Automata Raises $45M Series C to Build the Operating System for AI-Ready Labs
LONDON–(BUSINESS WIRE)– #aiml–Automata, the lab automation company building fully integrated, AI-ready platforms for life sciences, today announced the close of a $45 million Series C funding round led by Dimension with participation from Danaher Ve…
Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI™
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 million through the su…
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced that the U.S. Food and Drug Administration (F…
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S….
Following Merger, Advancing Sight Network and Miracles In Sight Become Precision Ocular Network
BIRMINGHAM, Ala. & CLEMMONS, N.C.–(BUSINESS WIRE)–Advancing Sight Network and Miracles In Sight today announced Precision Ocular Network as the new name and brand of their combined organization, following the merger unveiled in November. The new iden…
Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis
HEIDELBERG, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)– #FDA–Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and D…